CXCR2 and pancreatic adenocarcinoma: In pancreatic adenocarcinoma (PDAC), genetic depletion of CXCR2 prevented neutrophil accumulation and improved T cell entry, which contributed to tumor suppression and therapeutic response of anti-PD-1 (180, 181).